Aligos Therapeutics and Xiamen Amoytop Biotech: A Strategic Collaboration for Liver Disease Treatmen

Introduction Aligos Therapeutics, Inc., a renowned clinical-stage biopharmaceutical company, and Xiamen Amoytop Biotech Co. Ltd., a leading Chinese pharmaceutical company, have recently announced a research collaboration. This partnership is centered on Aligos' oligonucleotide platform, aiming to discover and develop effective oligonucleotide compounds for liver disease treatment in the Greater China territory. A Look at Aligos Therapeutics, Inc. Aligos Therapeutics, Inc., founded in 2018, is a clinical-stage biopharmaceutical company. The company's mission is to establish itself as a global leader in treating liver diseases and viral infections. Aligos' strategy focuses on leveraging its team's expertise and experience in liver and viral diseases to discover and develop cutting-edge therapeutic solutions. Aligos' Primary Focus The company's primary focus is on diseases with a high unmet medical need, such as nonalcoholic steatohepatitis (NASH), coronaviruses, and chronic hepatitis B (CHB). About Xiamen Amoytop Biotech Co. Ltd. Xiamen Amoytop Biotech Co. Ltd., a leading Chinese pharmaceutical company, is known for its innovative approach towards developing therapies for liver diseases. The Research Collaboration in Detail The research collaboration between Aligos and Amoytop centers around the use of Aligos' oligonucleotide platform for the discovery, research, and development of oligonucleotide compounds for liver disease treatment. The Agreement Under the terms of the agreement, Aligos and Amoytop will collaborate on the research and development of oligonucleotide compounds. Amoytop will receive an option to obtain an exclusive license to develop and commercialize the resultant products in the Greater China territory. Aligos, however, will retain the rights for the rest of the world. The Financial Aspect As part of the agreement, Aligos will receive an upfront payment and research collaboration funding. In addition to this, the company is also eligible to receive up to a total of $109 million in development and sales milestone payments for licensed products, as well as tiered royalties on net sales. Quotes from Key Figures "We are pleased to begin our collaboration with Amoytop, a leading Chinese domestic pharmaceutical company developing innovative therapies for liver diseases," said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos. "Our team has remained committed to developing drug candidates with the potential to improve the lives of patients living with viral and liver diseases, and we believe this research collaboration will help us to move closer to achieving that goal.” Sun Li, Chairman & CEO at Amoytop added, “We believe Aligos’ oligonucleotide platform has the potential to help our teams discover and develop novel candidates for liver diseases in China. We look forward to working together to advance new treatment options for patients in need.” Conclusion This strategic collaboration between Aligos and Amoytop is a promising step forward in the development of novel therapeutics for liver diseases. Through this partnership, both companies aim to leverage their respective strengths and expertise to bring about a significant improvement in the treatment of liver diseases, particularly in the Greater China territory. References:

Synapse: Global Drug Intelligence Database